A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Early Breast Cancer
Interventions: DRUG: SIBP-01|DRUG: Herceptin|DRUG: Docetaxel|DRUG: Carboplatin
Sponsor: Shanghai Institute Of Biological Products
Collaborators: Fudan University